Study of OST-122 in Patients With Moderate to Severe Ulcerative Colitis

Study Purpose

A Phase Ib/IIa to evaluate the safety and tolerability of oral treatment with OST-122 in patients with moderate to severe ulcerative colitis over 28 days. This trial will also explore pharmacokinetics (PK) profile and preliminary therapeutic efficacy associated with OST-122 through biomarker analysis and clinical, endoscopic and histologic assessments.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.

Searching Both is inclusive of interventional and observational studies.

Eligible Ages 18 Years - 75 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Willing and able to provide written informed consent and capable of understanding and complying with the protocol; 2. Patients male and female ≥ 18 and ≤ 75 years at the time of consent; 3. Patient with previous diagnosis of ulcerative colitis: ulcerative proctitis, left-side ulcerative colitis or extensive/pancolitis (E1, E2 and E3 of Montreal Classification, respectively) established at least 3 months prior to screening and determined by standard clinical, endoscopic, and histological procedures; 4. Demonstrated inadequate response, loss of response, or intolerance to at least one of the following treatments including, aminosalicylates (ASAs), corticosteroids, immunosuppressants, anti-tumor necrosis factor (TNF)-α agents or integrin inhibitor; 5. If the subject is currently receiving an oral aminosalicylate, he or she is eligible and can stay on that dose of aminosalicylate provided the dose has been stable for at least 1 week prior to screening; 6. If the subject is currently receiving an oral corticosteroid, he or she is eligible if the dose is equivalent to or less than prednisone 20 mg/day or beclomethasone dipropionate 5 mg/day and stable for at least 1 week prior to screening visit; 7. Has an endoscopic Mayo subscore of ≥ 2 and a total Mayo score of 5-10 during screening; 8. Women who are not postmenopausal (at least 12 months) or surgically sterile must have a negative pregnancy test at screening and at the end of study and either abstain from sexual intercourse or use a highly effective method of birth control (double barrier) for the duration of the study and after 12 weeks after the last dose of study drug; 9. For men: agreement to remain abstinent or use contraceptive measures and agreement to refrain from donating sperm for the duration of the study and after 12 weeks from the last dose of study drug; 10. Availability for the entire study period, absence of intellectual problems likely to limit the validity of consent to participate in the study or the compliance with protocol requirements; willingness to adhere to the protocol requirements, ability to cooperate adequately and to understand and follow the instructions of the physician or designee.

Exclusion Criteria:

1. Has fulminant colitis, toxic megacolon, primary sclerosing cholangitis, Crohn's disease, history of moderate to severe colitis-associated colonic dysplasia, active peptic ulcer disease; 2. Medications of exclusion: 1. Topical mesalazine or steroids (i.e., enemas or suppositories) within the 7 days prior to Baseline visit 2. Azathioprine, 6-mercaptopurine, or methotrexate within 10 days prior to Baseline visit, 3. Intravenous corticosteroids within the 14 days prior to Baseline visit, 4. Tofacitinib or any other JAK inhibitor within 14 days prior to Baseline visit; 5. Anti-diarrheal treatment within14 days prior to Baseline Visit. 6. Received cyclosporine, tacrolimus, mycophenolate mofetil, or thalidomide within 30 days prior to Baseline visit. 7. Adalimumab within the 30 days prior to Baseline visit 8. Infliximab, golimumab, etanercept, vedolizumab or certolizumab within the 60 days prior to Baseline visit 9. NSAIDs on a daily basis withdrawn 7 days previous to Baseline visit 3. Has a current bacterial, parasitic, fungal, or viral infection; 4. Is positive for hepatitis A, B or C, HIV or tuberculosis, as assessed by method available at each site; 5. Patient who has clinically significant diseases and/or infections captured in the medical history or evidence of clinically significant findings on physical examination and/or clinically significant ordinary laboratory evaluations (haematology, biochemistry, and urinalysis) or ECG; 6. Participated in another clinical trial of an investigational drug (or medical device) within 30 days prior to Baseline (or within 60 days prior to Baseline if investigational drug was a biologic product); 7. Demonstrated an inadequate response or loss of response to Tofacitinib or any other JAK inhibitor; 8. Use of products, food supplements or medical devices, whose composition includes probiotics in the 1 month prior to Baseline visit. 9. Patient who has prior extensive colonic resection, subtotal or total colectomy or planned surgery for ulcerative colitis; 10. Patient who has past or present fistula or abdominal abscess; 11. Patient who is pregnant or lactating; 12. Inability to comply with study protocol, in opinion of the investigator; 13. History of alcohol, drug or chemical abuse within 6 months prior to Screening visit; 14. History of cancer within the last 5 years. Patients with local basal or squamous cell carcinoma of the skin that has been excised and is considered cured may be included;

Trial Details

Trial ID:

This trial id was obtained from, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.


Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1/Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Oncostellae S.L
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Overall Status Not yet recruiting

The disease, disorder, syndrome, illness, or injury that is being studied.

Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe
Additional Details

OST-122 is an oral, gut-restricted and subtype-selective Jak3/Tyk2/Ark5 inhibitor for the local treatment of inflammatory bowel disease (IBD) including ulcerative colitis, Crohn's disease and, potentially, fibrotic lesions in Crohn's patients. The compound was well tolerated in a Phase 1 study in healthy volunteers and has been shown to be stable during the GI transit, while no significant plasma levels were detected. The gut-restricted PK profile of OST-122 lowers the risk of systemic toxicities inherent to other JAK inhibitors. In the current proof of concept study, the compound's safety, PK profile and trends of efficacy will be investigated in patients with moderate to severe ulcerative colitis.

Arms & Interventions


Active Comparator: Experimental arm OST-122 low dose

12 subjects will be randomized to receive low dose OST-122 orally daily for 28 days

Active Comparator: Experimental arm OST-122 high dose

12 subjects will be randomized to receive high dose OST-122 orally daily for 28 days

Placebo Comparator: Control arm Placebo

8 subjects will be randomized to receive placebo orally daily for 28 days


Drug: - OST-122

Active dose

Drug: - Placebo


Contact Information

This trial has no sites locations listed at this time. If you are interested in learning more, you can contact the trial's primary contact:

For additional contact information, you can also visit the trial on

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation. For a full description of terms please refer to our Terms, Conditions & Privacy.